Some OTC Switch Benefits Are Intangible, But Influential – CDER’s Ganley
This article was originally published in The Pink Sheet Daily & The Rose Sheet
Executive Summary
Non-measurable benefits can tip the scales in the benefit-risk consideration of an OTC switch NDA, suggests Charles Ganley, director of CDER's Office of Drug Evaluation. One way to look at non-measurable benefits is OTC ingredients "lower the threshold” for patient “misery” prior to seeking relief, he says.
You may also be interested in...
CDER Benefit/Risk Assessment Tool Has Room For OTC Considerations
A new benefit/risk framework for drug reviews currently being tested in FDA requires incremental considerations to apply to OTC reviews, a CDER official says. Former NDAC chairman Brass says FDA’s model is compatible with a separate OTC assessment framework developed for industry.
CHPA Quantifies OTCs’ Overall Value To Promote Expanded Access
Information from the CHPA-commissioned study could help improve policymakers’ understanding of the costs of making OTCs less available as well as the benefits of more Rx-to-OTC switches.
Prilosec 1 Use For GERD Endorsed In 16-2 Joint Committee Vote
Possible long-term use of omeprazole to prevent chronic heartburn or gastroesophageal reflux disease (GERD) is acceptable, despite an OTC indication for only 14-day use, FDA advisory committee members determined at a meeting in Bethesda, Md. June 21